---
title: "Our Development Pipeline"
title-block-banner: "./img/back3.jpg"
---

## Advancing Novel Immunotherapy from Preclinical to Clinical Development

VAXIMM's pipeline is built on our versatile oral T-cell immunotherapy platform designed to combat cancer through multiple mechanisms.

Our lead candidate, **VXM01**, is an oral immunotherapy that activates T-cells against VEGFR2, a key protein in tumor vasculature. This process destroys the tumor's blood supply and increases the infiltration of immune cells, with broad anti-tumor activity observed in preclinical and clinical studies.

Building on this validated approach, we are advancing a portfolio of preclinical assets targeting other critical cancer pathways. Together, these programs represent a deep and diversified strategy to address unmet needs in oncology.

::: {.accordion .accordion-flush #pipelineAccordion}

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm01">
<button class="accordion-button collapsed py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm01" aria-expanded="false" aria-controls="collapseVxm01">
<div class="w-100">
<p class="fw-bold text-start mb-1">VXM01 - Glioblastoma + Avelumab</p>
<div class="progress" role="progressbar" aria-label="Phase I/II progress" aria-valuenow="50" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-success" style="width: 50%;">Preclinical -- Phase I/II Complete</div>
</div>
</div>
</button>
</h2>
::: {.accordion-collapse .collapse #collapseVxm01 data-bs-parent="#pipelineAccordion"}
::: {.accordion-body}
A Phase I/II trial evaluating VXM01 in combination with avelumab, a human anti-PD-L1 antibody, for the treatment of glioblastoma has been completed. The trial is part of a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.

VXM01 has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioblastoma.

Learn more about the study (NCT03750071) [here](https://www.clinicaltrials.gov/ct2/show/NCT03750071).

:::
:::
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm01Glio">
<button class="accordion-button collapsed py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm01Glio" aria-expanded="false" aria-controls="collapseVxm01Glio">
<div class="w-100">
<p class="fw-bold text-start mb-1">VXM01 - Glioblastoma</p>
<div class="progress" role="progressbar" aria-label="Phase I progress" aria-valuenow="33" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-info" style="width: 33%;">Preclinical -- Phase I Complete</div>
</div>
</div>
</button>
</h2>
::: {.accordion-collapse .collapse #collapseVxm01Glio data-bs-parent="#pipelineAccordion"}
::: {.accordion-body}
A Phase I pilot study was designed to evaluate the safety and tolerability of VXM01, as well as clinical and immunogenic response, in patients with recurrent glioblastoma.

Fourteen patients were treated with VXM01, including three who were also treated with the anti-PD-1 checkpoint inhibitor, nivolumab. Of the fourteen patients treated, one patient experienced an objective response with VXM01 monotherapy and a durable response with the addition of nivolumab. During the observation period of up to 20 months, seven patients were still alive, all of them living for more than one year.

Learn more about the study (NCT02718443) [here](https://www.clinicaltrials.gov/study/NCT02718443).
:::
:::
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm01Panc">
<button class="accordion-button collapsed py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm01Panc" aria-expanded="false" aria-controls="collapseVxm01Panc">
<div class="w-100">
<p class="fw-bold text-start mb-1">VXM01 - Pancreatic Cancer</p>
<div class="progress" role="progressbar" aria-label="Phase I progress" aria-valuenow="33" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-info" style="width: 33%;">Preclinical -- Phase I Complete</div>
</div>
</div>
</button>
</h2>
::: {.accordion-collapse .collapse #collapseVxm01Panc data-bs-parent="#pipelineAccordion"}
::: {.accordion-body}
A Phase I trial in advanced pancreatic cancer showed that VXM01 was well tolerated and led to the activation of VEGFR2-specific cytotoxic T-cells, which was associated with significantly improved patient survival.

The data have been published [@niethammer_double-blind_2012; @schmitz-winnenthal_anti-angiogenic_2015; @schmitz-winnenthal_phase_2018].
:::
:::
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm04">
<button class="accordion-button non-collapsible py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm04" aria-expanded="false" aria-controls="collapseVxm04">
<div class="w-100">
<p class="fw-bold text-start mb-1">Undisclosed Target</p>
<div class="progress" role="progressbar" aria-label="Preclinical progress" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-secondary" style="width: 15%;">Preclinical</div>
</div>
</div>
</button>
</h2>
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm06">
<button class="accordion-button non-collapsible py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm06" aria-expanded="false" aria-controls="collapseVxm06">
<div class="w-100">
<p class="fw-bold text-start mb-1">Undisclosed Target</p>
<div class="progress" role="progressbar" aria-label="Preclinical progress" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-secondary" style="width: 15%;">Preclinical</div>
</div>
</div>
</button>
</h2>
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm08">
<button class="accordion-button non-collapsible py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm08" aria-expanded="false" aria-controls="collapseVxm08">
<div class="w-100">
<p class="fw-bold text-start mb-1">Undisclosed Target</p>
<div class="progress" role="progressbar" aria-label="Preclinical progress" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-secondary" style="width: 15%;">Preclinical</div>
</div>
</div>
</button>
</h2>
:::

::: {.accordion-item}
<h2 class="accordion-header unanchored" id="headingVxm10">
<button class="accordion-button non-collapsible py-2" type="button" data-bs-toggle="collapse" data-bs-target="#collapseVxm10" aria-expanded="false" aria-controls="collapseVxm10">
<div class="w-100">
<p class="fw-bold text-start mb-1">Undisclosed Target</p>
<div class="progress" role="progressbar" aria-label="Preclinical progress" aria-valuenow="15" aria-valuemin="0" aria-valuemax="100" style="height: 25px;">
<div class="progress-bar progress-bar-striped progress-bar-animated bg-secondary" style="width: 15%;">Preclinical</div>
</div>
</div>
</button>
</h2>
:::

:::

### References

::: {#refs}
:::